Neutropenia in patients treated with clozapine during COVID-19 infection
European psychiatry : the journal of the Association of European Psychiatrists
; 64(Suppl 1):S658-S658, 2021.
Article
in English
| EuropePMC | ID: covidwho-2045052
ABSTRACT
Introduction Clozapine is the most effective antipsychotic for treatment resistant schizophrenia but adverse reactions to clozapine include neutropenia. Patients with COVID-19 infection frequently experience lymphopenia, but not neutropenia.The impact of clozapine treatment in the presence of COVID-19 is unknown Objectives Show 2 cases of neutropenia in patients treated with long-term clozapine during COVID-19 infection. Methods Subjects:
48 admitted patients to a long-stay psychiatric unit. COVID-19 infection confirmed by positive nasopharyngeal swab for viral ribonucleic acid of SARS-CoV-2. Hematological controls between March and April 2020. Results 16 patients (33%) treated with clozapine.18 patients (37’5%) had COVID-19 infection, of which 5 (10’4%) were treated with clozapine;2 presented neutropenia. 1- 56-year-old woman diagnosed with schizophrenia on clozapine since 2009. Begins to have a dry cough and fever with positive COVID-19 swab (day 0). Slight leukopenia without neutropenia was observed on day 1. On day 7, neutropenia was observed with an absolute neutrophil count (ANC) of 1100. We decided to suspend clozapine and to initiate daily hematological controls. The ANC on day 8 was 970. Over the next few days the ANC will progressively improve until neutropenia resolved (day 22). 2- 55-year-old woman who required a transfer to a general hospital because of respiratory complications from COVID-19. She presented significant leukopenia (1’01x 10
Search on Google
Collection:
Databases of international organizations
Database:
EuropePMC
Language:
English
Journal:
European psychiatry : the journal of the Association of European Psychiatrists
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS